The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prognostic value of estrogen receptor (ER) and progesterone receptor (PR) expression levels in de novo and recurrent HR+/HER2- metastatic breast cancer (MBC) patients (pts) treated with CDK4/6 inhibitors (CDK4/6i) and endocrine therapy (ET): Real-world evidence.
 
Renata Duchnowska
No Relationships to Disclose
 
Katarzyna Soter
No Relationships to Disclose
 
Katarzyna Pogoda
Honoraria - AstraZeneca; Gilead Sciences; Lilly; MSD Oncology; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Gilead Sciences; Novartis; Sandoz
Speakers' Bureau - AstraZeneca; Gilead Sciences; Lilly Poland; Novartis; Pfizer
Travel, Accommodations, Expenses - AstraZeneca; Novartis
 
Justyna Zubrowska
No Relationships to Disclose
 
Aleksandra Grela-Wojewoda
No Relationships to Disclose
 
Karolina Winsko-Szczesnowicz
No Relationships to Disclose
 
Marek Szwiec
No Relationships to Disclose
 
Agnieszka Kowalewska-Felczak
No Relationships to Disclose
 
Iwona Danielewicz
No Relationships to Disclose
 
Tomasz Lewandowski
No Relationships to Disclose
 
Joanna Streb
No Relationships to Disclose
 
Bartosz Szymanowski
No Relationships to Disclose
 
Joanna Kiszka
No Relationships to Disclose
 
Ewa Kalinka
Honoraria - AstraZeneca; Bristol-MYERS SQUIBB; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; GlaxoSmithKline; Immutep; MSD; Nektar; Regeneron; Roche
Consulting or Advisory Role - Adamed; AstraZeneca; Bristol-Myers Squibb; Gilead Sciences; MSD Oncology
Speakers' Bureau - Bristol-Myers Squibb; Roche
Research Funding - AstraZeneca; Bristol-Myers Squibb; Merck Sharp & Dohme; Nektar; Roche
Travel, Accommodations, Expenses - Gilead Sciences; MSD; Roche
 
Bartlomiej Tomasik
No Relationships to Disclose
 
Barbara Radecka
No Relationships to Disclose
 
Maria Litwiniuk
No Relationships to Disclose
 
Aleksandra Lacko
No Relationships to Disclose
 
Anna Balata
No Relationships to Disclose
 
Michal Bienkowski
No Relationships to Disclose